Floatz logo

SDM-8

Psychiatric Disorder

Universitaire Ziekenhuizen KU LeuvenSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Psychiatric Disorder cohort.

Asset / SponsorPhaseRating
Liraglutide
Anders Fink-Jensen, MD, DMSci
Phase 4BB
SIMVASTATIN
Mclean Hospital
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
Losartan
Mclean Hospital
Phase 4BB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Bo Hu
Phase 2/3B

View all 15 →

Same molecule, other indications

SDM-8 is also rated in:

multiple sclerosisDormant
C
Indicative ·
34 / 100
View asset →
Lewy body dementiaDormant
D
Indicative ·
30 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →